INFINITT Teams With Medicsight To Offer FDA Cleared Virtual Colonoscopy With ColonCAD API
INFINITT North America, a leading provider of image and information management technologies for healthcare, recently announced a marketing partnership with Medicsight PLC to offer an FDA-cleared, integrated ColonCAD API package within its Xelis Colon application for improved detection of abnormalities within the large intestine.
CT Colonography (CTC), or virtual colonoscopy, is a low dose CT scan of the cleansed and gas-distended colon performed to detect polyps and masses. Advantages of CTC over conventional optical colonoscopy methods are that there is no sedation required, it is minimally invasive and it can be performed following an incomplete optical colonoscopy. CTC has received endorsement from the American Cancer Society among other organizations.
ColonCAD API is an advanced Computer-Aided Detection (CAD) algorithm which analyzes scan data and automatically highlights specific regions of interest that are indicative of potential colorectal polyps, thus helping radiologists to identify abnormalities within the colon that may be the early precursors of potential life threatening disease. With more radiologists learning to interpret CTC exams, it is anticipated that CAD will become an integral component of CTC interpretation.
The FDA clearance of ColonCAD API was supported by a large clinical trial involving 15 radiologist readers who each reviewed 112 CT colonography cases, both unassisted and assisted by ColonCAD. When assisted by ColonCAD, it was employed as a second reader to support radiologists in their evaluation after they had made an initial review of all the CTC image data. Cases were from a mixture of symptomatic and asymptomatic patients. The clinical trial results demonstrated that, when assisted by ColonCAD, radiologists' accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading.
The standalone performance of ColonCAD API 3.1 was also demonstrated using a validation database of cases independent of those used to train the CAD:
- 92.6% sensitivity in detecting polyps = 10mm
- 87.6% sensitivity in detecting polyps = 5mm
Colorectal cancer is the third most common cancer in men and the second in women worldwide.1 The combination of ColonCAD API - with its proven ability to increase radiologists' performance for the detection of polyps in CT colonography - and INFINITT's state-of-the-art Xelis application provides physicians with the support they need to detect this deadly disease at the earliest possible stage.
About ColonCAD
API Medicsight ColonCAD API is an industry leading software tool that aims to release the full potential of CT colonography. Medicsight ColonCAD API is indicated for use as a second-reader which prompts readers to potential polyps that may have been overlooked during initial review. ColonCAD API has been developed using a large and population diverse database of verified patient CT colonography scan data to support use with all patients referred for CTC; patients symptomatic of colorectal disease, or asymptomatic colorectal screening patients. It can be used with a broad assortment of CTC patient preparation protocols inclusive of fluid and fecal tagging regimes, and supports data from all CT scanner manufacturers.
About INFINITT North America
INFINITT North America, located in Phillipsburg, New Jersey, is an affiliate of INFINITT Healthcare, a global company with more than 2000 PACS installations worldwide. Infinitt's web-based image and information management solutions include RIS, PACS, Cardiology PACS, Mammo PACS and 3D/Advanced Visualization software operating on a single database, simplifying workflow, increasing system reliability, and reducing cost and support requirements. For more information, visit www.infinittna.com
SOURCE: INFINITT North America